KPRX — Kiora Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $13.37m
- -$17.91m
- 61
- 99
- 69
- 90
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2.69 | 0.012 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9.8 | 8.11 | 14 | 12.3 | 12.6 |
Operating Profit | -7.11 | -8.1 | -14 | -12.3 | -12.6 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7 | -8.08 | -14 | -13.7 | -12.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -7.1 | -8.09 | -13.8 | -13.6 | -12.5 |
Net Income Before Extraordinary Items | |||||
Net Income | -7.1 | -8.09 | -13.8 | -13.6 | -12.5 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -7.1 | -8.09 | -13.8 | -13.6 | -13 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -803 | -642 | -423 | -167 | -20.7 |